12,894 Shares in Revvity, Inc. (NYSE:RVTY) Purchased by XTX Topco Ltd

XTX Topco Ltd bought a new stake in shares of Revvity, Inc. (NYSE:RVTY) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,894 shares of the company’s stock, valued at approximately $1,352,000.

Several other large investors have also recently made changes to their positions in RVTY. Rothschild Investment LLC purchased a new stake in shares of Revvity during the second quarter valued at $25,000. Logan Capital Management Inc. purchased a new position in Revvity in the fourth quarter worth about $37,000. Family Firm Inc. bought a new stake in shares of Revvity during the 2nd quarter valued at about $43,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Revvity during the 2nd quarter valued at about $43,000. Finally, Parallel Advisors LLC purchased a new position in shares of Revvity in the fourth quarter worth approximately $47,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Price Performance

NYSE:RVTY opened at $122.89 on Friday. The business’s 50-day moving average is $119.06 and its 200 day moving average is $110.57. Revvity, Inc. has a 12 month low of $79.50 and a 12 month high of $128.15. The company has a market capitalization of $15.16 billion, a P/E ratio of 101.56, a P/E/G ratio of 2.87 and a beta of 1.05. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, July 29th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The firm had revenue of $691.70 million during the quarter, compared to the consensus estimate of $690.33 million. During the same period in the prior year, the company earned $1.21 EPS. The company’s quarterly revenue was down 2.5% compared to the same quarter last year. On average, equities research analysts forecast that Revvity, Inc. will post 4.75 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be issued a $0.07 dividend. The ex-dividend date is Friday, October 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.23%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Insider Activity

In other Revvity news, insider Joel S. Goldberg sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total transaction of $412,510.00. Following the sale, the insider now directly owns 33,400 shares of the company’s stock, valued at $3,936,524. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Barclays increased their price target on shares of Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 30th. TD Cowen upped their price target on Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Citigroup lifted their price objective on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Jefferies Financial Group raised their target price on shares of Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research note on Monday, July 29th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 30th. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.